Peloton Interactive, Inc. Announces Participation in the UBS Global TMT Conference

NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Peloton Interactive, Inc. (Nasdaq: PTON) today announced that the Company will be participating in the UBS Global TMT Conference, held at the New York Hilton Midtown Hotel in New York City, on Monday, December 9, 2019, at 8:30 AM ET. Attending for Peloton will be John Foley, Co-Founder & Chief Executive Officer, and Jill Woodworth, Chief Financial Officer.

The audio portion of the presentation will be webcast live over the internet and can be accessed at https://investor.onepeloton.com. An online archive will be available for a period of 90 days following the presentation.

About Peloton

Peloton is the largest interactive fitness platform in the world with a loyal community of over 1.6 million Members. The company pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its Members anytime, anywhere. We make fitness entertaining, approachable, effective, and convenient, while fostering social connections that encourage our Members to be the best versions of themselves. An innovation company at the nexus of fitness, technology, and media, Peloton has reinvented the fitness industry, creating a product that its Members love. The brand’s immersive content is accessible through the Peloton Bike, Peloton Tread, and Peloton App, which provides a full slate of fitness offerings, anytime, anywhere, through iOS and Android as well as most tablets and computers.

Founded in 2012 and headquartered in New York City, Peloton has a growing number of retail showrooms across the US, UK, Canada and Germany. For more information, visit www.onepeloton.com.

Investor Relations Contact: Peter Stabler, ICR [email protected] 

You May Also Be Interested In

• Backyard Discovery Expands Galvanized Steel Lineup Across Play, Patio and Garden with New Atlas Swing Sets, Ridgeline Louvered Pergolas and Larkspur Greenhouse
• XYone Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of XYA02(AT2021), a Novel Antibody Drug Conjugate targeting MUC1-C
• Powerhouse+Co. Named One of the Nation’s Top Franchise PR Firms